Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency
European Journal of Cancer · 2023-03 · 181 · 3-17
DOI: 10.1016/j.ejca.2022.11.028 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2023-03. Verfasst von Marie-Christine Etienne-Grimaldi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Oncopharmacology, Centre Antoine Lacassagne, Nice, France. Hauptthemen laut MEDLINE: Dihydropyrimidine Dehydrogenase Deficiency. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 108 Literaturangaben.
Abstract (Originalsprache)
Fluoropyrimidine drugs (FP) are the backbone of many chemotherapy protocols for treating solid tumours. The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine dehydrogenase (DPD), and deficiency in DPD activity can result in severe and even fatal toxicity. In this review, we survey the evidence-based pharmacogenetics and therapeutic recommendations regarding DPYD (the gene encoding DPD) genotyping and DPD phenotyping to prevent toxicity and optimize dosing adaptation before FP administration. The French experience of mandatory DPD-deficiency screening prior to initiating FP is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Oncopharmacology, Centre Antoine Lacassagne, Nice, France.
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, INSERM UMRS1138, Centre de Recherche des Cordeliers, F-75006 Paris, France.
- Université de Paris, INSERM UMRS1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
- SMARTc, CRCM INSERM U1068, Université Aix-Marseille, Marseille, France; Laboratory of Pharmacokinetics and Toxicology, Hôpital Universitaire La Timone, F-13385 Marseille, France; COMPO, CRCM INSERM U1068-Inria, Universi…
- Regional Center of Pharmacovigilance, Department of Pharmacology, Hôpital Cochin, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France; French Pharmacovigilance Network, France.
- Laboratory of Biochemistry and Molecular Biology, Centre Hospitalo-uinversitaire de Tours, Tours, France; INSERM U1248, IPPRITT, University of Limoges, Limoges, France.
Zitieren
APA
Etienne-Grimaldi, M. C., Pallet, N., Boige, V., Ciccolini, J., Chouchana, L., Barin-Le Guellec, C., Zaanan, A., Narjoz, C., Taieb, J., Thomas, F., Loriot, M. A., & Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER (2023). Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. European Journal of Cancer, 181, 3-17. https://doi.org/10.1016/j.ejca.2022.11.028
Vancouver
Etienne-Grimaldi MC, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, et al. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. European Journal of Cancer. 2023;181:3-17. doi:10.1016/j.ejca.2022.11.028
BibTeX
@article{EtienneGrimaldi2023,
author = {Etienne-Grimaldi, Marie-Christine and Pallet, Nicolas and Boige, Valérie and Ciccolini, Joseph and Chouchana, Laurent and Barin-Le Guellec, Chantal and Zaanan, Aziz and Narjoz, Céline and Taieb, Julien and Thomas, Fabienne and Loriot, Marie-Anne and Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER, Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER},
title = {Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency},
journal = {European Journal of Cancer},
year = {2023},
volume = {181},
pages = {3--17},
doi = {10.1016/j.ejca.2022.11.028}
}
EUVIMED